 Emil "Tom" Frei III (1924-2013) was an American physician and oncologist. He was the former director and former physician-in-chief (now emeritus) of the Dana-Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School. Frei received his undergraduate degree from Colgate University in 1944 and his medical degree from Yale University in 1948. He interned at St. Louis University Hospital and served as a physician in the Korean War. He worked at the National Cancer Institute from 1955 to 1965 and the M. D. Anderson Cancer Center from 1965 to 1972; while at M.D. Anderson he was the founding director of the Department of Development Therapeutics, which evolved into the Clinical Research Center. He served as physician-in-chief at the Dana-Farber Institute from 1972 to 1991. He is best known for his work on the treatment of lymphomas and childhood and adult leukemia. Frei was one of the founders of the Acute Leukemia Group B which later evolved into the Cancer and Leukemia Group B (CALGB). He served as the group chair for 16 years, from 1956-1963, and again from 1981-1990. In 1972 he received the Lasker-DeBakey Clinical Medical Research Award from the Lasker Foundation "for his outstanding contribution in application of the concept of combination chemotherapy for lymphoma and acute adult leukemia." Other awards included the Jeffrey A. Gottlieb Memorial Award (1978); NIH Distinguished Alumni Award (1990); Fellow, American Academy of Arts and Sciences (1999); Pollin Prize for Pediatric Research (2003); and AARC Lifetime Achievement Award (2004). 
